| # | Drug | Count |
|---|---|---|
| 0 | OXALIPLATIN | 110 |
| 1 | FLUOROURACIL | 108 |
| 2 | FLUOROURACIL CREAM, 0.5% | 108 |
| 3 | GEMCITABINE HYDROCHLORIDE | 43 |
| 4 | GEMCITABINE | 40 |
| 5 | SITAGLIPTIN | 27 |
| 6 | PACLITAXEL | 25 |
| 7 | METFORMIN | 19 |
| 8 | METFORMIN ER 500 MG | 19 |
| 9 | METFORMIN ER 750 MG | 19 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | DORAVIRINE | 2 | 0.0025 |
| 1 | OXALIPLATIN | 110 | 0.0014 |
| 2 | FLUOROURACIL CREAM, 0.5% | 108 | 0.0014 |
| 3 | FLUOROURACIL | 108 | 0.0014 |
| 4 | GEMCITABINE HYDROCHLORIDE | 43 | 0.0008 |
| 5 | PIOGLITAZONE AND METFORMIN HYDROCHLORIDE | 1 | 0.0008 |
| 6 | NATEGLINIDE | 1 | 0.0007 |
| 7 | IRINOTECAN HYDROCHLORIDE | 6 | 0.0005 |
| 8 | FLUDROCORTISONE ACETATE | 1 | 0.0004 |
| 9 | GOLIMUMAB | 5 | 0.0004 |
| # | Drug class | Count |
|---|---|---|
| 0 | Nucleoside Metabolic Inhibitor [EPC] | 122 |
| 1 | Platinum-based Drug [EPC] | 115 |
| 2 | Microtubule Inhibitor [EPC] | 33 |
| 3 | GLP-1 Receptor Agonist [EPC] | 23 |
| 4 | Corticosteroid [EPC] | 13 |
| 5 | Insulin Analog [EPC] | 13 |
| 6 | Nonsteroidal Anti-inflammatory Drug [EPC] | 12 |
| 7 | CD20-directed Cytolytic Antibody [EPC] | 11 |
| 8 | Proton Pump Inhibitor [EPC] | 10 |
| 9 | Folate Analog Metabolic Inhibitor [EPC] | 9 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Nucleoside Metabolic Inhibitor [EPC] | 122 | 0.0004 |
| 1 | Platinum-based Drug [EPC] | 115 | 0.0004 |
| 2 | Bispecific CD20-directed CD3 T Cell Engager [EPC] | 1 | 0.0002 |
| 3 | Poly(ADP-Ribose) Polymerase Inhibitor [EPC] | 5 | 0.0002 |
| 4 | Glinide [EPC] | 2 | 0.0002 |
| 5 | Microtubule Inhibitor [EPC] | 33 | 0.0002 |
| 6 | CD30-directed Immunoconjugate [EPC] | 2 | 0.0002 |
| 7 | Phosphodiesterase 3 Inhibitor [EPC] | 1 | 0.0002 |
| 8 | Provitamin D2 Compound [EPC] | 3 | 0.0001 |
| 9 | Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] | 2 | 0.0001 |